Affinity Groups
There are no Affinity Groups associated with this topic. View All Affinity Groups.
Announcements
There are no announcements with this tag. View All Announcements.
Upcoming Events & Trainings
No events or trainings are currently scheduled.
Topics from Ask.CI
Loading topics from Ask.CI ...
Knowledge Base Resources
| Title | Category | Tags | Skill Level |
|---|---|---|---|
| Fine-tuning LLMs with PEFT and LoRA | Video | fasteroptimizationperformance-tuning +1 more tags | Intermediate, Advanced |
Engagements
Recruiting
Re-engineering Lilly’s KisunlaTM into a novel antibody targeting IL13RA2 against GBM using AI-driven macromolecular modeling
Atrium Health Levine Cancer
- Summary and objectives of the proposed experiments:
- An initial research-based Ab (scFv47, discovered by our collaborator Dr. Balyasnikova) model, modeling Ab-Ag (IL13RA2 against GBM) protein complex, and identifying the binding sites (epitopes) using ROSETTA and AlphaFold2 multimer tools.
- Graft the CDRs of scFv (single-chain variable fragment) of antibody or Bispecific T cell engagers (BTEs) onto the template Ab, the framework of Lilly's Kisunla™ Ab drug.
- Modify, improve, and optimize the overall or full antibody protein structures using AI-driven macromolecule modeling (AlphaFold3).
- Explore single nucleotide polymorphism (SNP), pathogenic genetic variants and N-glycosylation of IL13RA2 (target) protein domain interacting with the Ab candidates among the patient population using ROSETTA software packages.
Status: Recruiting
People with Expertise
Expertise
Expertise
Expertise
People with Interest
Doug Heckman
Rochester Institute of Technology
Programs
Campus Champions
Roles
research computing facilitator
Interests
Interests
Programs
CCMNet
Roles
CCMNet
